Quality of Life in Psoriasis: A Cross-Sectional Study from North India
- PMID: 38572024
- PMCID: PMC10986881
- DOI: 10.4103/ijd.ijd_144_23
Quality of Life in Psoriasis: A Cross-Sectional Study from North India
Abstract
Background: Psoriasis is a chronic inflammatory papulo-squamous disease characterized by multiple remissions and relapses. This study aimed to assess the impact of psoriasis on the quality of life of patients.
Materials and methods: A hospital-based, cross-sectional study was conducted enrolling 198 adult patients of psoriasis. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for observational studies were followed. Clinical severity of psoriasis was measured using Psoriasis Area Severity Index (PASI), and quality of life was measured by EuroQoL 5D (EQ-5D-5L, EQ-VAS) and Psoriasis Quality-Of-Life-12 (PQOL-12) Questionniares.
Results: Of the 198 patients, 71.7% (n = 142/198) were males with a mean age of 41.65 ± 13.19 years. The mean PASI score was 12.46 ± 11.51, and the mean PQOL-12 score was 50.18 ± 23.36. Up to 22.7% (n = 45) cases had 'severe' and 6.1% (n = 12) cases has 'very severe' PQOL-12 scores. Statistically significant correlation (P < 0.05) was observed between PASI scores and almost all domains of EQ-5D-5L and PQOL-12.
Conclusion: Psoriasis affects most psycho-social domains of a patient's life. Coping with these QOL issues remains a challenge to the patients in everyday life. The goal of management of psoriasis therefore must include measures to improve quality of life along with long-lasting remittance of physical symptoms.
Keywords: Pasi; QOL; psoriasis; quality of life.
Copyright: © 2024 Indian Journal of Dermatology.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Pasi and pqol-12 score in psoriasis: is there any correlation?Indian J Dermatol. 2011 May;56(3):287-9. doi: 10.4103/0019-5154.82482. Indian J Dermatol. 2011. PMID: 21772589 Free PMC article.
-
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.Qual Life Res. 2017 Dec;26(12):3409-3419. doi: 10.1007/s11136-017-1699-x. Epub 2017 Sep 5. Qual Life Res. 2017. PMID: 28875430
-
EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.J Med Econ. 2017 Jan;20(1):19-27. doi: 10.1080/13696998.2016.1219359. Epub 2016 Aug 15. J Med Econ. 2017. PMID: 27471948
-
Health state utility values derived from EQ-5D in psoriatic patients: a systematic review and meta-analysis.J Dermatolog Treat. 2022 Mar;33(2):1029-1036. doi: 10.1080/09546634.2020.1800571. Epub 2020 Aug 9. J Dermatolog Treat. 2022. PMID: 32716651
-
Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis.Cochrane Database Syst Rev. 2020 May 5;5(5):CD011941. doi: 10.1002/14651858.CD011941.pub2. Cochrane Database Syst Rev. 2020. PMID: 32368795 Free PMC article.
References
-
- Mahajan R, Handa S. Pathophysiology of psoriasis. Indian J Dermatol Venereol Leprol. 2013;79((Suppl 7)):S1–9. - PubMed
-
- Al-Mazeedi K, El-Shazly M, Al-Ajmi HS. Impact of psoriasis on quality of life in Kuwait. Int J Dermatol. 2006;45:418–24. - PubMed
-
- Finlay AY, Kelly SE. Psoriasis--an index of disability. Clin Exp Dermatol. 1987;12:8–11. - PubMed
-
- Jacobson CC, Kimball AB. Rethinking the psoriasis area and severity index: The impact of area should be increased. Br J Dermatol. 2004;151:381–7. - PubMed
LinkOut - more resources
Full Text Sources